Literature DB >> 8316628

Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs.

M J Allalunis-Turner1, G M Barron, R S Day, K D Dobler, R Mirzayans.   

Abstract

Two aneuploid cell lines which differ in their inherent sensitivity to ionizing radiation and chemotherapeutic agents were established concurrently from a single tumor specimen obtained from a patient with glioblastoma. M059J cells are approximately 30-fold more sensitive to radiation than are M059K cells (surviving fractions at 2 Gy were 0.02 and 0.64, respectively). This relative difference in radiation sensitivity has remained a stable feature of the cell lines during 2 years in continuous culture. In addition, cells of the M059J line are more sensitive than those of the M059K line to the cytotoxic effects of bleomycin, N,N-bis(2-chloroethyl)-N-nitrosourea, and nitrogen mustard. These cell lines may prove to provide a useful model system for evaluating the cellular and molecular processes which confer resistance or sensitivity in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8316628

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  59 in total

1.  Induction and characterization of human glioma clones with different radiosensitivities.

Authors:  J Wang; L Hu; N Gupta; T Shamseldin; T Ozawa; J Klem; M Cardell; D F Deen
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Subnuclear localization of Ku protein: functional association with RNA polymerase II elongation sites.

Authors:  Xianming Mo; William S Dynan
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

3.  Biochemical evidence for Ku-independent backup pathways of NHEJ.

Authors:  Huichen Wang; Ange Ronel Perrault; Yoshihiko Takeda; Wei Qin; Hongyan Wang; George Iliakis
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

4.  Diverse roles for E4orf3 at late times of infection revealed in an E1B 55-kilodalton protein mutant background.

Authors:  Robin N Shepard; David A Ornelles
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes.

Authors:  Ian R Powley; Alexander Kondrashov; Lucy A Young; Helen C Dobbyn; Kirsti Hill; Ian G Cannell; Mark Stoneley; Yi-Wen Kong; Julia A Cotes; Graeme C M Smith; Ron Wek; Christopher Hayes; Timothy W Gant; Keith A Spriggs; Martin Bushell; Anne E Willis
Journal:  Genes Dev       Date:  2009-05-15       Impact factor: 11.361

6.  Lack of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is accompanied by increased CK2α' levels.

Authors:  Birgitte B Olsen; Ulrike Fischer; Tine L Rasmussen; Matthias Montenarh; Eckart Meese; Gerhard Fritz; Olaf-Georg Issinger
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

7.  hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks.

Authors:  R S Maser; K J Monsen; B E Nelms; J H Petrini
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

8.  DNA-PK is essential only for coding joint formation in V(D)J recombination.

Authors:  P Kulesza; M R Lieber
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

9.  Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells.

Authors:  Resham Lal Gurung; Shi Ni Lim; Aik Kia Khaw; Jasmine Fen Fen Soon; Kirthan Shenoy; Safiyya Mohamed Ali; Manikandan Jayapal; Swaminathan Sethu; Rajamanickam Baskar; M Prakash Hande
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

10.  Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response.

Authors:  Maria Quanz; Danielle Chassoux; Nathalie Berthault; Céline Agrario; Jian-Sheng Sun; Marie Dutreix
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.